Entity

Time filter

Source Type


Patent
Shin Nippon Biomedical Laboratories Ltd. | Date: 2013-03-14

Provided herein are methods for generating dry vaccine powder formulations. Dry vaccine powder formulations can be used for intranasal delivery. Also provided are methods for stimulating local mucosal and systemic immunity by intranasal vaccine delivery.


[Problem] To provide an OCT3 activity inhibitor having a different basic skeleton than that of conventional OCT3 activity inhibitors. [Solution] This inhibitor of organic cation transporter 3 (OCT3) contains, as an active component, an imidazo[1,2-a]pyridine derivative, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof


Patent
Shin Nippon Biomedical Laboratories Ltd. | Date: 2012-01-31

Devices for delivery of dry powder formulations are also provided. Devices can be single-use devices. Formulations and methods of manufacture are provided for dry powder compositions suitable for intranasal administration. Also provided are methods of use for preventing or controlling emesis and other diseases and disorders and devices, compositions, and methods for nasal delivery of therapeutic formulations.


Patent
Nagasaki University and Shin Nippon Biomedical Laboratories Ltd. | Date: 2013-02-13

To provide a peptide which can be produced and processed more readily compared with prothymosin , which is conventionally known, or a peptide thereof and has an activity at a level equivalent to or higher than that of prothymosin or a peptide thereof. The present invention provides an ameliorating agent for blood-organ barrier dysfunction, a therapeutic agent for diseases associated with blood-organ barrier dysfunction or ischemic diseases or a nerve cell death inhibitor, each comprising, as an active ingredient, a peptide comprising the amino acid sequence represented by SEQ ID NO: 1 or a peptide having substantially the same function as that of the aforementioned peptide.


Patent
Shin Nippon Biomedical Laboratories Ltd. | Date: 2010-08-02

Formulations and methods of manufacture are provided for granisetron dry powder compositions suitable for intranasal administration. Also provided are methods of use for preventing or controlling emesis and other diseases and disorders and devices, compositions, and methods for nasal delivery of therapeutic formulations. Devices for delivery of dry powder formulations are also provided. Devices can be single-use devices.

Discover hidden collaborations